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Background: To evaluate the effectiveness of a new multifactorial intervention to improve health care for chronic
ischemic heart disease patients in primary care. The strategy has two components: a) organizational for the
patient/professional relationship and b) training for professionals.
Methods/design: Experimental study. Randomized clinical trial. Follow-up period: one year. Study setting: primary
care, multicenter (15 health centers). For the intervention group 15 health centers are selected from those
participating in ESCARVAL study. Once the center agreed to participate patients are randomly selected from the
total amount of patients with ischemic heart disease registered in the electronic health records. For the control
group a random sample of patients with ischemic heart disease is selected from all 72 health centers electronic
records.
Intervention components: a) Organizational intervention on the patient/professional relationship. Centered on the
Chronic Care Model, the Stanford Expert Patient Program and the Kaiser Permanente model: Teamwork, informed
and active patient, decision making shared with the patient, recommendations based on clinical guidelines, single
electronic medical history per patient that allows the use of indicators for risk monitoring and stratification.
b) Formative strategy for professionals: 4 face-to-face training workshops (one every 3 months), monthly update
clinical sessions, online tutorial by a cardiologist, availability through the intranet of the action protocol and related
documents.
Measurements: Blood pressure, blood glucose, HbA1c, lipid profile and smoking. Frequent health care visits.
Number of hospitalizations related to vascular disease. Therapeutic compliance. Drug use.
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Discussion: This study aims to evaluate the efficacy of a multifactorial intervention strategy involving patients with
ischemic heart disease for the improvement of the degree of control of the cardiovascular risk factors and of the
quality of life, number of visits, and number of hospitalizations.
Trial registration: NCT01826929
Keywords: Health services research, Cardiovascular diseases, Primary care, Secondary preventionBackground
The medical, health care, financial, personal and family
burden of chronic disease is one of the main threats to
the sustainability of the health system. At present, 70%
of health care expenditure is used to treat chronic diseases
[1]. Accordingly, health care systems are now moving to-
wards more patient-centered models based on self-care
and therapeutic education as ways of promoting the par-
ticipation of the patients in their own treatment [2].
Cardiovascular disease (CVD) is one of the main chronic
diseases, and is in fact the leading cause of death in the
Spanish population. In 2007 it accounted for 124,126
deaths in Spain, representing 32% of all deaths [3]. In
Spain, ischemic heart disease (IHD) causes most CVD
deaths (30% overall; 37% in men and 24% in women). The
hospital morbidity rate for IHD was 317 per 100,000 in-
habitants (447 in men and 189 in women) [3–5].
Lifestyle changes (giving up smoking, a Mediterranean
diet and exercise) have been shown to decrease cardio-
vascular morbidity and mortality in patients with IHD.
In addition, much evidence now exists concerning
pharmacological treatment aimed at the associated risk
factors [5].
The latest European guidelines aim to increase the in-
volvement of the primary care professionals in the imple-
mentation of the preventive activities for these patients.
The guidelines emphasize a patient-centered approach,
joint decision-making, and the importance of establishing
realistic and feasible objectives, as tools to improve com-
pliance with medication and lifestyle changes [6–8]. A re-
cent Cochrane library review stresses the importance
of primary care and the need to improve the organization
of the health care services for the secondary prevention of
IHD [9].
However, difficulties exist when incorporating the re-
sults of the various studies into clinical practice. Com-
parison of the results from the EUROASPIRE I to the
EUROASPIRE III studies, in patients with IHD, shows
that the prevalence of risk factors remains high: smoking
hardly changed (20.3%, 21.2%, and 18.2%), obesity (body
mass index ≤ 30) increased from 25% to 32.6% and 38%,
and poorly controlled blood pressure (BP) (≥ 140/
90 mmHg) changed very little (58.1%, 58.3%, and 60.9%).
Only in the prevalence of hypercholesterolemia wasan important decrease observed, from 94.5% to 76.7%
and 46.2%. Concerning the use of drugs, between the
EUROASPIRE I and the EUROASPIRE III studies [10]
antiplatelet drugs rose from 80.8% to 93.2%, beta blockers
from 56% to 85.5%, antihypertensive drugs from 84.5% to
96.8%, and lipid-lowering drugs from 32.2% to 88.8%. Al-
though improvements have been noted, an important per-
centage of patients still exists in whom the control of risk
factors could be improved.
Studies carried out in our area show that 54% of the
patients with a history of myocardial infarction had
hypercholesterolemia, 41% had high blood pressure, 11%
were smokers, and 19% were obese; in addition, there
was a clear underuse of medication [11].
Therapeutic educational interventions, such as the
Chronic Care Model (CCM) that includes educational,
organizational and community participation interven-
tions; the Stanford Expert Patient Program (EPP); and
the Kaiser Permanente model [12,13] have all shown
their benefit in patients with a high CVD risk and their
effect on clinical measures and health care use.
Based on these models, various initiatives to improve
the secondary prevention of coronary disease patients
have been undertaken in our area [14,15]. The ICAR
study assessed the efficacy of an intensive secondary pre-
vention program of coronary disease carried out in primary
care. However, improvement was only found in blood
pressure control and an increase in HDL-cholesterol con-
centrations [14]. The PREseAP study assessed the efficacy
of an intervention carried out by nurses, but with no posi-
tive results [16,17]. Another intervention study also from
primary care [18] found that admissions to hospital were
significantly reduced, but no other clinical benefits were
shown, possibly because of a ceiling effect related to im-
proved management of the disease. Given these poor re-
sults, we designed a multifactorial intervention based on
the CCM, integrating professionals from cardiology ser-
vices and primary care, in an attempt to improve the de-
gree of control of CVRF and reduce the number of
hospital admissions.
Main objective
To evaluate the effectiveness of a new multifactorial inter-
vention in order to improve health care for chronic IHD
2.
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components: a) organizational for the patient/professional
relationship, and b) formative for the professionals.
Specific objectives
Level of control/follow-up of the following variables:
blood pressure, capillary blood glucose, HbA1c, LDL
cholesterol, body mass index, therapeutic compliance,
exercise, smoking, adherence to a Mediterranean diet,
incidence of hospital admissions related to vascular dis-
ease, annual primary care visits (number of visits in one
year) and drug use (antiplateled drugs, beta blockers,
ACE inhibitors/ARA II, statins).
Hypothesis
A multifactorial primary care intervention based on
chronic models [12] can improve the level of control




Experimental design. Type of study: open randomized
clinical trial. Follow-up period: one year.
Participants
Setting: Primary Health Care. Valencian Community
(Spain).
15 Health centers: Alicante-Cabo-Huertas, Alicante-
Campello, Alicante-Plà Hospital, Castellón-Dolores-Cano-
Royo-Villareal, Castellón-La-Bobila-Villareal, Castellón-
Cariñena-Villareal, Castellón-Nules, Castellón-Vall d’Uxo
I and II; Valencia-S Pau, Valencia-R-Argentina, Valencia-
Benimaclet and Valencia-Serreria-II.
Inclusion criteria: patients with a diagnosis of IHD of
any site (ICD-10 codes from 410 to 414 inclusive); age
from 30 to 80 years; signed written informed consent.
Exclusion criteria: lack of consent; immobilized patients;
patients with serious health problems or with a low life
expectancy.
Data are collected from electronic health record system.
Interventions
Organized intervention strategy aimed at patients and
professionals:
1. Organized intervention strategy:
a) Informed active patient. By means of
therapeutic education of the patient according
to the CCM recommendations and following
the Stanford EPP model. To promote patient
autonomy: self-measurement of blood pressure
and blood glucose control. Use of
recommendations for patients in a uniformformat and content for all the professionals
using the recommendation forms for patients
with chronic diseases (hypertension, diabetes,
IHD, obesity, smoking) available in the
electronic medical history.
b) Shared decision making. Personalized control
objectives. To seek ways of promoting the
increased participation of chronic patients in
their treatment and the sharing of decisions.
Creation of a patient follow-up record showing
the state of the different study variables. The
achievement of the objectives is evaluated with
a traffic light type graph identifying the degree
of compliance in the colors green, amber or
red. Personalized and agreed objectives are
established for each patient and shown on the
record (see Figure 1). The IHD patient care
protocol of the SVMFiC (2010 update) is used
[19], available via the Abucasis intranet. The
criteria used to define good control of the
variables (Table 1) are those of the
Cardiovascular Disease Prevention Group of
the Preventive Activity and Health Promotion
Program (PAPPS) [5].
c) Appointment planning. Every three months,
although variable depending on the patient, to
provide time to evaluate the agreed changes.
At nurse/patient visits to assess: diet, exercise and
therapeutic compliance at 2 weekly sessions every
3 months (Tables 2 and 3).
d) Primary care doctor-nurse teamwork. Joint work
with agreed aims in a basic primary care health
unit.
e) Actions based on scientific evidence. Work
following electronically available protocols
validated by scientific societies integrated in the
Valencian Medical Institute. Communication with
the cardiology service, to facilitate the
interconsultation between primary and secondary
care.
f ) To promote information systems through a single
electronic history shared between primary and
secondary care. Evaluation of indicators of
program follow-up.
Formative intervention strategy for professionals:
a) Formative. Four face-to-face workshops
(every 3 months); monthly clinical session on
cardiovascular disease; online tutorials with the
cardiology service to solve any doubts. Face-
to-face tutorials with a team, reference
doctor/nurse, in each health center.
b) Strategies to avoid clinical inertia: carry out
therapeutic changes if there is poor control
before 3 months.
Figure 1 Personalized follow-up record.
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Primary outcome measure: number of hospitalizations/
cause. It is measured at the beginning and end of the
study.
Secondary outcomes:
a) Level of control of CVRF: Blood pressure, LDL
cholesterol, body mass index, basal blood glucose,
HbA1c, therapeutic compliance (pill count),
smoking. They are measured at each visit.
b) Healthy life habits: Exercise, mediterranean diet.
They are measured at each visit.
c) Management: Number of annual primary care visits.
It is measured at the end of the study.Table 1 Therapeutic objectives
Variable Objective
Basal blood glucose < 126 mg/dl
HbA1c < 7%;
Blood pressure ≤140/90 mmHg
LDL cholesterol ≤ 100 mg/dl
Therapeutic compliance* 80-110%
Practice of exercise 30 minutes per day > 3 days per week
Mediterranean diet Validated survey.
(*)Pill count.To enhance the quality of measurements a training
program is performed and there was one assessor for
every three health centers.Sample size
The calculation of the sample size is carried out to com-
pare means, with an alpha risk of 0.05 (95% confidence
level) and a beta risk of 0.20 (80% power). For an esti-
mated difference in SBP of 5 mmHg and a standard de-
viation of SBP of 2.5 mmHg, the number of persons
necessary is 251 patients per group. Increased by 20%
for possible losses, giving a total of 301 patients in each
group.
Randomization, allocation and implementation
Valencia is a Mediterranean Spanish Region with 5 mil-
lion inhabitants. In 2007, 800 primary care physicians
and nurses started the ESCARVAL primary prevention
cohort study [20]. 72 Health centers (HC) participated
including 50000 patients.Table 2 Primary care visit timeline
Visit timeline
Follow-up months 1 2 3 4 5 6 7 8 9 10 11 12
Nurse √ √ √ √ √ √ √ √
Physician √ √ √ √
Table 3 Task distribution in the follow-up clinics
Risk factors Physician Nurse
1 Assess Abucasis register. ++ ++
2 Establish personalized objectives. ++ ++
3 Assess degree of control. ++ ++
4 Assess therapeutic compliance. + ++
5 Assess attitude towards each objective. ++ ++
6 Agree interventions with the patient. ++ ++
7 Adequate pharmacological treatment. ++ -
8 Individual intervention. ++ ++
9 Team intervention. - ++
10 Community intervention. - ++
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HC are selected from those participating in ESCARVAL.
Once the center agreed to participate patients are ran-
domly selected from the total amount of patients with
IHD registered in the electronic health records.
For the control group a random sample of patients
with IHD is selected from all 72 HC electronic records.
Patients are enrolled by their primary care physicians
who will offer to participate to the randomly selected
patient.
Blinding
Blinding is not possible as the intervention is a multifac-
torial approach. That’s why the control group is selected
after the intervention is made but for the same period of
time.
Statistical analysis
The results are expressed as frequencies and percentages
for qualitative variables and as mean and standard devi-
ation for the quantitative variables. For the statistical
analysis, the study of categorical variables is carried out
by the ×2 test and the comparison of the continuous var-
iables between groups of patients by the Student t test
and ANOVA. A multivariate analysis will be carried out
to evaluate the effect of the intervention. The SPSS PC
15.0 program will be used.
The reference search was performed in the Medline
database through PubMed. The MeSH terms used were:
“Myocardial Ischaemia/prevention and control” [Mesh]”
OR “Myocardial Ischaemia/epidemiology” [MeSH],
OR “Coronary Artery Disease”[MeSH Terms] AND
“Secondary prevention”. A second search included:
“Patient Education” as Topic/methods OR “Patient
Participation” OR “Self-Help Groups” OR “Program
Evaluation” AND “Myocardial Ischaemia”.
In the Cochrane database we used the MeSH terms:
Patient Education, Lifestyle.The search was limited to publications in the last
5 years, only items with abstracts, studies in humans,
and a publication type of Meta-Analysis and Systematic
Review. In the Cochrane database we also used the
search limit of the last 5 years.
Follow-up
Table 4 shows the follow-up plan and patient data col-
lection. Functions of the professionals participating in
the study are described in Table 5.
Figure 2 provides a flow diagram of the study.
Ethical and legal issues
This study protocol has been reviewed and approved by
the Ethics Committee for Clinical Trials from San Juan
de Alicante Hospital (Comite Ético de Investigación
Clínica (CEIC) del Hospital Universitario de San Juan de
Alicante), on December 2nd, 2009.
The study is conducted according to the standards
of the International Guidelines for Ethical Review of
Epidemiological Studies (Council for International
Organizations of Medical Sciences- CIOMS-Geneva,
1991) and the recommendations of the Spanish Society of
Epidemiology about the review of ethical aspects of epi-
demiological research.
Confidentiality of the data
All information relative to the patient’s identity is con-
sidered confidential. The data generated during the
study will be handled according to the Law 5/1999 and
corresponding normative. Any researcher with access to
the data used in the study will be required to sign a
document guaranteeing confidentiality.
Informed consent
All patients must read the “Patient Information Form”
and sign a document giving their consent.
Discussion
IHD is one of the main causes of death despite the great
capacity for prevention that is available. Nowadays, mul-
tiple therapeutic tools of proven efficacy exist to control
the main CVRF, as well as guidelines and protocols en-
dorsed by the main scientific societies [5–7,19].
However, the degree of control of the CVRF in pa-
tients with IHD is low [15–17], which results in a higher
use of health services. The frequency of primary care
visits of a person with diabetes in Spain is 28 per year,
even though this does not necessarily imply greater
control [21]. Two of the main reasons for this are
lack of treatment compliance and therapeutic inertia
in the office, control of which has not improved in recent
years [22–25].
Table 4 Follow-up plan and collection of patient data
Enrolment allocation Intervention group:
15 HC selected from those participating in ESCARVAL-risk study.
350 patients randomly selected from the total amount of patients with IHD registered in the electronic health
records.
Patients are enrolled by their primary care physicians. (Inclusion and exclusion criteria).
Control group:
A random sample of patients (350) with IHD selected from 72 HC electronic records (from ESCARVAL-risk study)
Intervention follow-up: 1 year Baseline data
Personalized follow-up record
Starting formative intervention strategy for professionals and patients:
Intervention Patients Professionals
First visit Evaluate monitoring of CVRF Advice online by cardiologist
Accord control objectives Monthly updates
Adherence control Protocols, guides and bibliography reviews
Therapeutic education In-class training course
Second visit Evaluate monitoring of CVRF Advice online by cardiologist
Accord control objectives Monthly updates
Adherence control Protocols, guides and bibliography reviews
Therapeutic education In-class training course
Third visit Evaluate monitoring of CVRF Advice online by cardiologist
Accord control objectives Monthly updates
Adherence control Protocols, guides and bibliography reviews
Therapeutic education In-class training course
Number of hospital admissions
Outcomes Statistical analysis. Loses to follow-up.
Presentation of results at participating HC.
Final report
HC, Health Center.
Table 5 Functions of the professionals participating in
the study
Functions of each professional in the study
Primary care physicians/
nurses:
- Identification of patients to include.
- Inclusion and contact with patients.
- Adaptation of therapeutic interventions.
- Therapeutic compliance.
Reference cardiologists
and group of experts
- Workshop teaching.
- Online tutorials.




- Analysis of the data and interpretation of
the results
Abucasis responsible - Facilitate the use of the electronic
medical history through response to
doubts or information about not very
used resources.
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new approaches. These models involve patient training to
achieve greater autonomy and information, and the identi-
fication of high-risk patients to give them a more individu-
alized and protocolized care.
Accordingly, the present study involved an organizational
intervention based on CCM together with an educational
intervention, integrating cardiology service professionals
and primary care professionals (general practitioners and
nurses), in an attempt to improve the degree of control of
CVRF and decrease the number of hospitalizations.
This intervention aims to increase the degree of self-
control for these patients as well as their ability for self-
care and decision making to improve their long-term
survival. At the same time, the greater degree of infor-
mation and education can facilitate the increase in com-
pliance that should result in an improvement in the
therapeutic objectives.
The health care team-work methodology will be modi-
fied with more resolute and specific patient-centered
Figure 2 Flow diagram of the PROPRESE study.
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primary care offices. This is aimed at reducing clinical
inertia.
The Abucasis computer system, available in secondary
and primary care offices, facilitates the interaction be-
tween levels of health care as well as being a common
and unique site for the patient to record and control the
main CVRF.
The validity of the results, which depends on the rep-
resentativeness of the sample, is controlled by the selec-
tion criteria designed and in relation to study power,
through the sample size calculated taking into account
any unexpected loss by controlling the random error.
Some multifactorial interventions have been published
specially based on nurse work [26] but no very good
results have been obtained. Our study has some different
aspects that can be mentioned: we use an unique electronic
health record for primary and secondary care improving
communication between professionals, we implement
CCM strategies involving patients with self-care, sharing
decisions about the level of control to be reached and ob-
jective based treatments, involving all primary care team
(physicians and nurses) and cardiologists.
In conclusion, this study will provide information about
the efficacy of a patient-centered intervention based on
the CCM. Actions will be centered on identifying the
higher-risk patients, such as those in secondary preven-
tion; on greater patient information and capacity, favoringautonomy; on shared decision making to establish and
reach the control objectives; and an individualized pro-
gramming of appointments, relying for all this on the
teamwork of primary care nurses and physicians under
the supervision of the reference cardiology service.
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